HK2 and neoplasm: 3BP (HK2), a hexokinase II inhibitor, reduces adenosine triphosphate (ATP) levels and lactic acid production by inhibiting glycolysis, which promotes the polarization of tumor-related macrophages (TAMs) toward anti-tumor M1 phenotypes.